As it is known that the expression of LGI1 is lower in several LEATs and other low-grade gliomas and that lower expression of LGI1 is involved in epilepsy patients and mouse models, we argue that LGI1 is a promising potential therapeutic target in the treatment of epileptogenic brain tumors in general, and LEATs specifically, although more research is needed to specify its role and the role of LGI autoantibodies exactly. The gene discussed is LGI1; the disease is central nervous system cancer.